Xentria Inc. announced a $25 million growth equity funding round approved by its Board of Directors and the opening of a new corporate headquarters.
Company unveils new Chicago headquarters in growing life sciences hub
CHICAGO--(BUSINESS WIRE)-- Xentria Inc., a biotech company focused on developing novel therapeutics to address unmet clinical needs, today announced a $25 million growth equity funding round approved by its Board of Directors and the opening of a new corporate headquarters.
Xentria researches and develops critical therapeutics. Its lead candidate, XTMAB-16, is being evaluated as a potential therapy for patients with sarcoidosis, a chronic, multisystem inflammatory disorder. XTMAB-16, a chimeric monoclonal antibody, may work to disrupt an important inflammatory pathway to help slow or stop granuloma formation in patients with sarcoidosis - a key differentiator for the company.
“This funding round is an important milestone for Xentria as we advance our pipeline and execute against our goal of developing critical therapeutics for patients in need,” said President of Xentria, Tom Shea.
As Xentria continues to advance the development of XTMAB-16, additional funding will allow the company to further strengthen the depth of its scientific and technical leadership and drive the clinical development process forward. XTMAB-16 recently completed a Phase 1 study which characterized pharmacokinetics and safety in healthy volunteers, and previously announced in vitro data that further demonstrated XTMAB-16’s potential ability to suppress granuloma formation in a dose-dependent fashion. Funds will also support next stage clinical development of XTMAB-16, including the launch of a global clinical trial in sarcoidosis expected to initiate in early 2023.
“I am excited about this round of funding and the momentum it will put behind our promising developments to date,” said Kirsten Anderson, Chief Operating Officer at Xentria. “Patients with sarcoidosis have limited treatment options. Expanding our world-class leadership team will ensure we have the right experience and expertise at the helm to support the development of XTMAB-16, effectively moving the needle towards accessible treatment options for people living with sarcoidosis.”
This financial milestone comes as the company unveils its new Chicago headquarters, at 2071 N Southport Ave. It is located adjacent to the exciting new neighborhood to be known as Lincoln Yards which will house other industry-leading companies seeking to develop medical solutions alongside a broader life sciences community.
“Innovation in health care and life sciences is accelerating in Chicago at an unprecedented pace,” said Michael Fassnacht, President & CEO, World Business Chicago, and Chief Marketing Officer, City of Chicago. “We congratulate Xentria for its funding raise and announcement of a new Chicago headquarters adjacent to Lincoln Yards. From the city’s rich ecosystem of world-renowned academic and research institutions, lab space, pharma and our supportive and well-connected ecosystem, Xentria is well-positioned here for incredible success.”
About Sarcoidosis
Sarcoidosis is a chronic, multisystem inflammatory disorder of unknown etiology that is characterized by the presence of non-caseating and non-necrotizing epithelioid granulomas (as opposed to granulomas caused by infections, such as tuberculosis), accompanied by infiltration of mononuclear cells and destruction of microarchitecture.
About XTMAB-16
XTMAB-16 is a chimeric human-murine IgG1 anti-TNF monoclonal antibody being developed as a novel biologic product for the treatment of sarcoidosis.
About Xentria
Xentria, whose name stems from the word “centrality”, was founded in 2020 and is an innovative biopharmaceutics company whose primary focus is to build an expansive product pipeline of cost-effective and efficacious therapeutics to address critical unmet need for patients suffering from rare diseases, immunologic disorders and oncological conditions. Headquartered in Chicago, with partners in Israel and China, the company is dedicated to research and development and clinical science, driven to treat the clinical and social burdens of diseases while fostering sustainable growth.
To learn more about Xentria visit www.xentria.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221018005301/en/
Contacts
FTI Consulting
Jacqui Wilmot, Senior Director
914.435.3863
jacqui.wilmot@fticonsulting.com
FTI Consulting
Erin Williams, Director
347.237.2043
erin.williams@fticonsulting.com
Xentria, Inc.
Noopur Singh, Director, Medical Affairs
contact@xentria.com
Source: Xentria Inc.
View this news release online at:
http://www.businesswire.com/news/home/20221018005301/en
